The first reporton the favorable impact of albumin binders on tumor uptake of targetedradiopharmaceuticals was presented by Cristina Müller and colleaguesin 2013 for a folate receptor ligand. Thelow-molecular-weight albumin binder Lys­(4-(p-iodophenyl)­butanoyl)–OH(Lys­(IPB)–OH) was used for functionalization based on the originaldiscovery of Dumelin et al. in 2008 showingthat this chemotype exhibits a binding affinity to albumin in thelow μM range. The gene discussed is ALB; the disease is neoplasm.